Loading
Judgment Score
72 /100

Strong Progress

Top 23% among M&A associates this month

+4 pts this week
Training Reps
7

Reps This Week

12 reps · best week

Weekly target: 5 reps
M
T
W
T
F
S
S
Firm Ranking
Top 23%
Among M&A associates
at your level this month
M&A Top 18%
Securities Top 31%
Cross-practice Top 41%
Practice Area Proficiency
M&A
82
Securities
71
Employment
54
Privacy/Data
48
Regulatory
61
IP
43
Antitrust
67
Recent Activity
CFIUS Review Triggers
M&A · Advanced · Mar 24
87
Non-Compete Ban: SaaS
Employment · Foundational · Mar 22
74
AI Copyright Exposure
IP · Intermediate · Mar 20
61
SEC Climate Disclosure
Securities · Intermediate · Mar 18
79
Data Broker Regs
Privacy/Data · Advanced · Mar 15
58
Your Judgment Profile
Three dimensions of legal judgment — developed through deliberate practice.
Connection Density
CD
Pattern Recognition
61 /100
Building your cross-domain library. 23 drills completed.
Anticipation Rate
AR
Signal Reading
Unlocks after 15 completed drills in a practice area. Trains the ability to read developments before they're obvious.
8/15 M&A
Situational Relevance
EQ
Advice Quality
58 /100
How well you tailor analysis to a specific client's needs. Measured in the Analysis phase of each drill.
Next Level Training
Signal Reads — Unlocks at Level 2
Once you've completed 15 drills in a practice area, you'll unlock Signal Reads — 3-minute pattern recognition exercises where you identify what a signal means before the outcome is revealed. The next layer of judgment training.
M&A Track: 8 of 15 drills to unlock 7 remaining
Why This Exists
Previous generations of lawyers built judgment through repetition — memos marked up by partners, analyses torn apart, rooms where they watched senior counsel read signals in real time. AI has absorbed most of that formative work. Acuity gives you back the reps.
Recommended for You
Based on a real legal development — recommended for your weak areas
SEC Climate Disclosure Rules: What Your PE-Backed Client Needs to Know
Your client Meridian Technologies (Thoma Bravo portfolio) is heading toward a Q3 2026 IPO. The SEC's enhanced climate disclosure rules are now in effect for large accelerated filers — but where does your client stand, and what do they need to do before the roadshow?
Securities Intermediate
10–12 min

SEC Climate Disclosure Rules: What Your PE-Backed Client Needs to Know

Securities Regulation Intermediate 10–12 min Published Mar 18, 2025
1
Scenario
2
Risk ID
3
Analysis
4
Score
Live Development — March 6, 2024
The SEC adopted final rules on climate-related disclosures for public companies. This is a real regulatory action. The scenario below places you in an advisory role responding to this actual development.
Your Client Scenario
The SEC climate disclosure rules just dropped. Your client, Meridian Technologies, is a PE-backed (Thoma Bravo) mid-market SaaS company generating $180M ARR. They're preparing for a potential IPO in Q3 2026. The CFO saw the headlines and called your senior partner, who just forwarded you the email: "What do we need to worry about? I need a memo by Thursday."

Meridian operates data centers in Texas, Virginia, and Frankfurt (EU). They have approximately 1,200 employees across the US, UK, and Germany. Their PE sponsor is planning a secondary offering concurrent with the IPO.

This scenario is based on the SEC's actual Enhanced Climate Disclosure Rules adopted March 6, 2024. The client is fictional; the legal development is real.
What a Senior Partner Sees Immediately
    Background Documents
    SEC Enhanced Climate Disclosure Rules (March 2024)
    Final Rule · 17 CFR Parts 210, 229, 232, 239, 240

    The SEC adopted final rules requiring registrants to disclose climate-related risks that have materially affected or are reasonably likely to materially affect their business strategy, results of operations, or financial condition. Key provisions include:

    • Scope 1 & 2 GHG emissions disclosure required for large accelerated filers beginning FY2025
    • Scope 3 emissions requirement was eliminated from the final rule (a significant change from the proposed rule)
    • Material climate-related risks and their quantified financial impacts
    • Climate-related governance — board oversight and management's role
    • Attestation requirements for large accelerated filers (limited assurance initially)
    • Safe harbor for forward-looking climate disclosures
    IPO Applicability & Transition Thresholds
    Accelerated Filer · Large Accelerated Filer · SRC Exemptions

    The rules apply on a phased basis depending on filer category. For IPO candidates, the relevant thresholds are:

    • Large Accelerated Filer (LAF): Public float ≥ $700M — most stringent requirements, FY2025 compliance
    • Accelerated Filer: Float $75M–$700M — similar requirements, one-year delayed phase-in
    • Non-Accelerated Filer / SRC: Float < $75M — limited requirements, later phase-in
    • New IPO registrants are generally not subject to the rules until after their first full fiscal year as a reporting company
    • However, S-1 disclosures must address known material climate risks under existing MD&A rules
    • PE-backed companies preparing for IPO should begin data collection 12–18 months in advance
    SEC Enforcement Actions & Recent Settlements
    ESG Washing · Material Misstatement · Recent Precedents

    The SEC's Climate and ESG Task Force (ESGTF) has been active since 2021. Key enforcement patterns relevant to IPO candidates:

    • Goldman Sachs ESG Fund (2022): $4M civil penalty for misleading ESG investment criteria disclosures
    • Vale S.A. (2023): $55M settlement for misrepresenting safety processes (analogous governance risk)
    • Scope creep risk: Companies that make voluntary ESG claims in marketing materials face scrutiny under anti-fraud provisions, even before mandatory rules apply
    • EU CSRD exposure: Meridian's Frankfurt operations trigger EU Corporate Sustainability Reporting Directive obligations for FY2026 — a separate but intersecting compliance track
    • Internal ESG data inconsistencies between investor presentations and S-1 disclosures have been a recurring SEC comment letter focus
    Identify the key risks and practice areas implicated by this scenario.
    Select all practice areas that are materially implicated. Consider the full scope of the engagement — not just the obvious issues.
    Describe the top 3 risks you'd flag for the CFO and your recommended next steps:
    Anticipation Rate — Commitment Gate
    Commit to a directional read before you see the expert analysis. Your commitment is locked once submitted. Calibration matters as much as correctness — a confident wrong answer scores lower than a tentatively wrong answer.
    Confidence:

    You identified 5 of 6 key areas

    Strong identification — you caught the core issues

    Direct Hits
    Partial
    Missed

    Your Analysis

    Your Written Analysis

    Expert Analysis

    Issue-by-Issue Feedback
    /10
    Issue Density
    /10
    Anticipation
    /10
    Situational Relevance

    Total Drill Score

    vs. your previous best
    +8 pts
    Improving

    Key area to develop: Tax cross-domain awareness. When advising PE-backed companies on compliance obligations, always run a concurrent analysis of available IRA and state tax credits. Associates who catch this earn 15–20% higher scores on multi-domain drills. Recommended: complete "IRA Tax Credits for Technology Companies" (Foundational, 8 min).

    Next Recommended Drill
    M&A M&A Track
    8 of 24
    8 of 24 drills complete 7 remaining to unlock Signal Reads
    Securities Securities Track
    4 of 24
    4 of 24 drills complete 11 remaining to unlock Signal Reads
    Employment Employment Track
    2 of 24
    2 of 24 drills complete 13 remaining to unlock Signal Reads
    72
    Current Judgment Score
    18
    Drills Completed
    7
    Reps This Week
    12
    CLE Credits Earned
    Judgment Dimensions
    Your development across the three dimensions of legal judgment.
    Connection Density
    61
    Pattern Recognition
    Anticipation Rate
    Signal Reading
    Unlocks at 15 drills / practice area
    Situational Relevance
    58
    Advice Quality
    Judgment Score — Last 30 Days
    Your Score
    Peer Average
    Practice Area Proficiency
    You
    Top Quartile
    Benchmarking — vs. Associates at Your Level
    M&A
    82 Top 18%
    Securities
    71 Top 31%
    Employment
    54 Top 52%
    Privacy/Data
    48 Top 61%
    Regulatory
    61 Top 44%
    IP
    43 Top 71%
    Antitrust
    67 Top 38%
    CLE Credits Tracker
    12 of 24 credits earned
    2026 Annual Goal
    50%
    Jan 1, 2026 Renewal: Dec 31, 2026
    Drill History
    Drill Practice Area Difficulty Date Score
    SEC Climate Disclosure RulesSecuritiesIntermediateMar 18, 202679
    CFIUS Review Triggers: TikTok PrecedentM&AAdvancedMar 24, 202687
    Non-Compete Ban: SaaS WorkforceEmploymentFoundationalMar 22, 202674
    AI-Generated Content: Copyright ExposureIPIntermediateMar 20, 202661
    Data Broker Regulations: GDPR Meets State LawsPrivacy/DataAdvancedMar 15, 202658
    Hart-Scott-Rodino: When Does It Apply?AntitrustFoundationalMar 12, 202681
    Section 16 Short-Swing Profits: PE FundsSecuritiesIntermediateMar 9, 202676
    Trade Secret Protection: Remote TeamsIPFoundationalMar 5, 202665
    23
    Active Associates
    +3 this quarter
    68
    Avg Judgment Score
    +11 pts since Jan
    84%
    Weekly Engagement Rate
    +12% vs last quarter
    247
    Drills Completed (Q1)
    +68% vs Q4 2025
    ROI Metrics
    +18%
    Average judgment score improvement over 90 days of active training
    Based on 23 associates · Wilson Sonsini cohort · Jan–Mar 2026
    +23%
    More billable hours logged by associates in the top training quartile in their primary practice area
    Compared to bottom quartile · Adjusted for seniority · Trailing 90 days
    Associate Roster
    Practice Area Heatmap — Firm Proficiency at a Glance
    Vertical attention map
    Engagement vs. press coverage
    Where GC attention is pooling — by sector × issue area
    7-day rolling. Cell intensity = relative GC engagement. Small italics under cell = press coverage rank for comparison.
    SEC Climate
    FERC 1920
    FDA AI/ML
    340B Litig.
    PE Disclosure
    DE Caremark
    Energy
    Mid
    press: high
    High
    press: low
    Low
    press: low
    Mid
    press: mid
    Life Sciences
    Low
    press: high
    High
    press: mid
    Hot
    press: low
    Mid
    press: mid
    Financial Services
    Mid
    press: mid
    Mid
    press: mid
    High
    press: low
    Hot
    press: mid
    Industrials
    Hot
    press: high
    Mid
    press: low
    Low
    press: low
    Mid
    press: mid
    Read the divergences
    Energy GCs are heavily focused on FERC Order 1920 with low press coverage — the press-vs-engagement gap is your edge in any energy-sector room. Life-sciences GCs are under-engaged with the SEC climate rule despite high coverage — calling that out signals you read the room, not the headlines.
    What GCs are engaging with this week — energy sector
    Top 10 · 7-day · ranked by relative dwell + return
    • 01
      FERC Order 1920 — transmission planning & cost allocation
      Active engagement at 38 of 47 energy-sector CB seats this week
      ▲ +42% wow
    • 02
      Texas SB 6 — large-load interconnection rules
      29 of 47 seats engaged; ERCOT exposure cohort dwelling 4.1× baseline
      ▲ +28% wow
    • 03
      SEC climate disclosure — Reg S-K Item 1500 readiness
      Engagement below press peak — pre-IPO & large accelerated filer cohort only
      — flat
    • 04
      RGGI & state-program interaction with federal climate rules
      Northeastern utility GCs only — narrow but deep engagement
      ▲ +19% wow
    • 05
      DOJ environmental crimes — knowing-violation theory
      Compliance officers + litigation-heavy GCs; up sharply post-DOJ memo
      ▲ +33% wow
    • 06
      PIPE & SEC Rule 144 — restricted security resale paths
      Private-equity-backed energy issuers
      — flat
    • 07
      Caremark refresh — board oversight in regulated industries
      DE-incorporated GCs, post-Pfizer ruling
      ▲ +14% wow
    Rising in GC engagement before press catches up
    Lead-time signal

    When the GC community starts engaging seriously with an issue weeks before the press cycle peaks, you can credibly tell a target's GC "I'm seeing your peers focus on this — here's why it lands in your shop in 60 days."

    FDA AI/ML guidance — pre-market clearance pathways
    7
    weeks ahead of press
    Life-sciences GC engagement on this topic has tripled over 7 weeks while press coverage remains low. Mid-cap biotechs with diagnostic-AI exposure are dwelling longest. Probable conversation in board rooms in the next quarter.
    PE continuation funds — LP fiduciary friction
    5
    weeks ahead of press
    PE-backed company GCs and fund counsel are engaging with ILPA template language and recent SEC private-fund-rule remand. The press has not yet picked up the LP-side complaint pattern.
    DOJ corporate-criminal — successor-liability theory in M&A
    4
    weeks ahead of press
    Industrial & manufacturing GCs are reading deeply on the new successor-liability framework; deal-team counsel haven't internalized it yet. Pre-diligence conversation opportunity.
    Practice-area heat — where GC attention is shifting
    30-day MoM change in engagement share
    PE / Fund Disclosure
    +240%
    MoM engagement
    ▲ Highest delta
    Securities Litigation
    +86%
    MoM engagement
    ▲ Rising
    FDA / Healthcare Reg
    +62%
    MoM engagement
    ▲ Rising
    Energy Reg (FERC)
    +44%
    MoM engagement
    ▲ Rising
    M&A / Deal Protection
    +12%
    MoM engagement
    — Steady
    Cap Markets
    −8%
    MoM engagement
    ▼ Cooling
    AI Governance
    −14%
    MoM engagement
    ▼ Press-loud, GC-flat
    ESG / Sustainability
    −22%
    MoM engagement
    ▼ Cooling
    Press is loud, GCs are quiet
    Inverse signal

    Where headline volume runs ahead of GC engagement. Either the press is over-covering, or the issue lands later. Either way: position-early opportunity.

    AI governance & corporate liability
    Press coverage up 180% YoY; GC engagement flat. Board agenda mentions remain rare. Plausible outcome: lands in 6–9 months once a major liability event forces it onto agendas. Partners who develop a defensible posture now will be first-call when it hits.
    Generative-AI training-data IP exposure
    Heavy press, light GC engagement outside tech-sector legal teams. Industrial & financial-services GCs not yet treating this as a personal risk. Window for proactive board memos.
    SEC cybersecurity disclosure — Item 106
    Press coverage steady; engagement declined 22% MoM. The first-wave compliance work has been done; second-wave (recurring incident reporting) hasn't yet hit GC reading lists.
    Filter by geography
    Reasons to call this week
    5 prompts
    Halcyon Pharma NASDAQ:HLCN · $2.4B mkt cap
    Target · Life Sciences · CA
    Halcyon's GC is engaging at peer-cohort rate on 340B litigation but is under-engaging on FDA AI/ML guidance. Halcyon's diagnostic-AI pipeline (per their 10-K) is materially exposed to the new pre-market clearance framework. That's a blind spot you can name in the first 90 seconds of a meeting.
    Engagement evidence
    Among 14 mid-cap biotech GCs in CB's life-sciences cohort, FDA AI/ML guidance is the #1 most-engaged issue this week. Halcyon GC engagement on this issue: below cohort 25th percentile.
    Open with the FDA AI/ML angle. Soft inroad: ask whether their Q3 board materials will address it.
    Meridian Technologies
    Active client · Energy · TX
    FERC Order 1920 is the #1-engaged issue across Meridian's energy-sector peers this week. Press is barely covering it — but Meridian's Q3 IPO timing puts them inside the first transmission-cost-allocation cycle. Reg S-K Item 1500 readiness is the conversation everyone else is having; FERC 1920 is the conversation that wins the room.
    Engagement evidence
    38 of 47 energy-sector GCs in CB engaged with FERC 1920 this week (+42% wow). Press coverage rank: low. The press-vs-engagement gap is the partner edge.
    Sarah Chen, GC. Last touch: Series D close, March. Lead with FERC 1920, not climate disclosure.
    Northwind Industrial
    Target · Manufacturing · TX
    8-K filed yesterday: $400M revolver replacement, JPM led, no Latham involvement disclosed. Their last public credit work was 2023. Industrial-sector GCs in CB are also engaging heavily on DOJ successor-liability theory — adjacent to upcoming bolt-on M&A activity Northwind has signaled.
    Engagement evidence
    DOJ successor-liability is engaging 7 weeks ahead of press in industrial-sector GC reading. Northwind's M&A roadmap intersects directly.
    Reach via Kim Patel (Bracewell). Pitch: credit + M&A successor-liability framework.
    Aerolux Holdings
    Alumni client · Aerospace · DE
    Delaware Chancery ruled Thursday on In re Pfizer Stockholder Litigation — Corwin cleansing now requires deeper disclosure on special-committee process. Aerolux's announced take-private makes this directly material. Caremark refresh is also rising in DE-incorporated GC engagement.
    Engagement evidence
    DE-incorporated GCs engaged with Caremark refresh issues +14% wow. Aerolux's GC: above cohort median — receptive audience.
    David Reyes, GC. Refresh on take-private timing; offer Corwin/Revlon/MFW process memo.
    Trellis Capital Partners
    Target · PE Sponsor · NY
    Continuation-fund secondaries are rising in PE-fund GC engagement 5 weeks ahead of press. Trellis raised a $1.8B Fund VI in 2023 — continuation-fund mechanics for portfolio rebalancing are exactly the conversation their LP base will start asking about within the quarter.
    Engagement evidence
    ILPA continuation-fund template language: +86% MoM in PE-fund counsel reading.
    Marcus Webb, GP. Pitch: LP-side fiduciary friction memo & ILPA-aligned process template.
    Full watchlist
    23 companies
    Company Status Sector / Geo Last touch Press signal Peer-GC signal
    Meridian Technologies Client Energy · TX Mar — Series D Hot
    +42% FERC 1920
    Halcyon Pharma Target Life Sci · CA Warm
    −68% Blind spot
    Northwind Industrial Target Manuf · TX Feb — TXEC dinner Warm
    +33% DOJ succ.
    Aerolux Holdings Alumni Aerospace · DE 2024 — Take-private Hot
    +14% Aligned
    Trellis Capital Partners Target PE · NY Warm
    +86% Cont. fund
    Bayou Midstream Client Energy · TX Apr — JV closing Warm
    +24% FERC 1920
    Civita Health Target Life Sci · NY Quiet
    +91% 340B
    Stellata Power Target Energy · CA Quiet
    +19% RGGI
    Cordillera Resources Alumni Energy · CO 2023 — Reorg Quiet
    +8% DOJ env.
    Trinity Wind Target Energy · TX Warm
    +38% SB 6
    Filter by geography
    Energy & Power
    7 watchlist targets · 47 peer-GC seats in CB cohort · last 7 days
    What\'s moving (press)
    • SEC climate disclosure rules — Reg S-K Item 1500
    • ERCOT winter reliability & PUCT Phase II
    • EPA Clean Power Plan 2.0 litigation
    • State PUC AI-load tariff proceedings
    • ESG-disclosure pushback & Texas anti-ESG laws
    What GCs are engaging with
    • FERC Order 1920 — transmission planning & cost allocation (96% engagement)
    • Texas SB 6 — large-load interconnection (78%)
    • SEC climate — but only pre-IPO & LAF cohort (62%)
    • RGGI/state-program federal interaction (54%)
    • DOJ environmental crimes — knowing-violation theory (48%)
    Divergence — your edge
    Press leads with SEC climate; GCs in the energy cohort lead with FERC 1920 (low press coverage, +42% wow engagement). Walking into an energy-sector room with the FERC 1920 framing is what nobody else has.
    Your targets in this vertical
    • Meridian TechnologiesClient · FERC 1920 hot
    • Bayou MidstreamClient · FERC 1920 +24%
    • Trinity WindTarget · SB 6 +38%
    • Stellata PowerTarget · RGGI +19%
    • Cordillera ResourcesAlumni · DOJ env. +8%
    Life Sciences
    3 watchlist targets · 22 peer-GC seats in CB cohort · last 7 days
    What\'s moving (press)
    • HRSA v. Sanofi & the 340B program
    • FTC pharma-merger enforcement
    • SEC climate disclosure for biotechs
    • FDA AI/ML pre-market clearance
    • Inflation Reduction Act drug-pricing litigation
    What GCs are engaging with
    • FDA AI/ML guidance — diagnostic-AI pipelines (#1 cohort engagement, 7wk lead)
    • 340B litigation post-HRSA — narrow but deep
    • DE Caremark refresh post-Pfizer (board duty-of-oversight)
    • SEC climate — only pre-IPO biotechs
    • FTC pharma-merger — flat engagement despite press
    Divergence — your edge
    Press is heavy on HRSA/Sanofi and FTC enforcement; cohort GCs are quietly going deep on FDA AI/ML guidance — 7 weeks ahead of press. Diagnostic-AI exposure is the conversation that lands.
    Your targets in this vertical
    • Halcyon PharmaTarget · FDA AI/ML blind spot
    • Civita HealthTarget · 340B +91%
    Private Equity & Sponsor Finance
    4 watchlist targets · 18 peer-GC seats in CB cohort · last 7 days
    What\'s moving (press)
    • SEC private-fund-rule remand
    • Add-on M&A volume & antitrust scrutiny
    • ESG-investor pushback on PE
    • Carry tax proposals
    What GCs are engaging with
    • Continuation funds & LP fiduciary friction — ILPA template (5wk lead)
    • DOJ successor-liability in M&A — 4wk lead
    • SEC private-fund rule — narrowed post-remand
    • NVCA term-sheet revisions for AI portcos
    Divergence — your edge
    Press is on SEC private-fund rule; GC fund counsel is engaging on continuation-fund LP friction (5 weeks ahead) and DOJ successor-liability theory in bolt-on M&A (4 weeks ahead). Both are conversations the press hasn\'t framed yet.
    Your targets in this vertical
    • Trellis Capital PartnersTarget · cont. fund +86%
    This week\'s lead connection
    Cross-target · cross-practice
    Trigger development

    FERC Order 1920 — final transmission planning & cost-allocation rule

    Issued Tuesday. Mandates regional 20-year transmission planning and revises cost-allocation methodology. Press coverage: low. The implication chain reaches further than the order itself, and it touches your book three different ways.

    Engagement evidence — why this is the room\'s conversation
    38 of 47 energy-sector GCs in CB engaged with FERC 1920 this week (+42% wow, #1 issue in cohort). Press coverage rank: low. The press-vs-engagement gap is unusually wide — partners who lead with FERC 1920 will sound prescient.
    Adjacent inference chain — the role-differentiated lens
    • 1st-order (any reader): transmission planning is now regional and longer-horizon. Cost allocation shifts toward beneficiary-pays.
    • 2nd-order (energy specialist): ISOs/RTOs must update their tariff filings within 12 months — large-load interconnection queues will be re-prioritized in the same cycle.
    • 3rd-order (cross-domain — your edge): for portcos in energy-adjacent industrials and AI/data-center developers, project economics will reprice as cost-allocation methodology shifts. M&A diligence on energy-exposed assets will need a FERC 1920 readiness chapter within 90 days. PE sponsors with grid-exposed portfolios should pre-empt LP questions.
    Touches in your book
    Client · open angle
    Meridian Technologies
    Q3 IPO timing intersects FERC 1920\'s first cost-allocation cycle. S-1 risk-factors update needed.
    Refresh meeting · S-1 amendment
    Client · open angle
    Bayou Midstream
    Recent JV transmission tie-in puts them in the first cost-allocation reassessment cohort.
    JV memo · cost-allocation chapter
    Target · cold-open path
    Trinity Wind
    Their planned ERCOT interconnection lands inside Texas SB 6 + FERC 1920 simultaneous compliance window.
    Cold open · regulatory framing memo
    Target · unrepresented
    Stellata Power
    Northeastern utility — RGGI/federal interaction × FERC 1920 cost-allocation creates novel rate-case posture.
    Cold open · novel rate posture
    Other connections worth working this week
    FDA AI/ML pre-market clearance guidance → Halcyon Pharma (target, blind-spot) + Civita Health (target, peer-aligned) + 1 unrepresented mid-cap biotech in your geo.
    3rd-order: diagnostic-AI portfolio companies of life-sciences PE sponsors will need board-level guidance memos within 60 days. Adjacent inference: medical-device makers using ML-driven calibration are inside the same framework even though they don\'t self-identify as AI.
    Engagement evidence
    FDA AI/ML guidance is #1 in life-sciences cohort engagement, 7 weeks ahead of press. Halcyon GC engagement: below cohort 25th percentile (named blind spot).
    ILPA continuation-fund template revisions → Trellis Capital Partners (target) + 2 unrepresented mid-market PE sponsors with vintage-2018+ funds.
    3rd-order: GP-led secondaries with single-asset rolls will face LP fiduciary-friction language in next-fund LPAs. Practical implication: GP advisory committees need a fairness-opinion process update before next AGM.
    Engagement evidence
    ILPA continuation-fund language: +86% MoM in PE-fund counsel reading, 5 weeks ahead of press.
    DE Chancery — In re Pfizer Stockholder Litigation → Aerolux Holdings (alumni, take-private in flight) + every DE-incorporated public company target.
    3rd-order: Caremark refresh + Corwin tightening = sponsors of carve-outs need to rebuild their special-committee process documentation playbook before next deal. Cross-practice angle: M&A + securities litigation + governance.
    Engagement evidence
    Caremark refresh engagement among DE-incorporated GCs: +14% wow. Aerolux GC: above cohort median.
    DOJ successor-liability framework in M&A → Northwind Industrial (target, bolt-on roadmap) + every industrial portco doing add-ons this cycle.
    3rd-order: pre-LOI diligence scopes need a successor-criminal-liability chapter; reps & warranties insurance carriers will start asking different questions in underwriting within 6 months.
    Engagement evidence
    DOJ successor-liability theory: +33% wow in industrial-sector GC engagement, 4 weeks ahead of press.
    Generate a brief
    Company Brief
    A target-specific brief with five things to know walking in, suggested practice angles, peer-cohort engagement signal, and what their GC is — and isn\'t — paying attention to.
    Recent
    • Halcyon Pharma — generated yesterday
    • Trellis Capital — generated 2d ago
    • Stellata Power — generated 3d ago
    Industry Brief
    A vertical primer for a conference panel or BD meeting in an industry you\'re ramping in. Press vs cohort engagement, lead-time signals, and the divergences that signal expertise.
    Recent
    • Energy & Power — generated today
    • Life Sciences — generated yesterday
    Conference / Event Prep
    A shortlist of attendees + hot conversation seeds drawn from peer-cohort engagement signal. The questions you can ask that nobody else can.
    Recent
    • TXEC Spring Summit — generated 5d ago
    Sample — Halcyon Pharma company brief
    Generated yesterday · 4 min read
    Halcyon Pharma · NASDAQ:HLCN · $2.4B mkt cap
    Mid-cap biotech · diagnostic-AI & oncology pipeline · CA-incorporated · GC: Andrea Liu

    Halcyon is a $2.4B mid-cap with a diagnostic-AI pipeline (3 FDA-cleared, 4 in submission) and a recently expanded 340B commercial relationship via Sanofi. They have not done a public capital-markets transaction since 2022. Their GC, Andrea Liu, joined from Bristol-Myers in 2024 — known to be cautious, regulatory-fluent, and skeptical of new outside counsel relationships without clear practice-area fit.

    1. Their diagnostic-AI pipeline is materially exposed to FDA AI/ML guidance — and their last public engagement on the topic predates the September draft.
    2. 340B litigation post-HRSA v. Sanofi creates direct contractual revisit risk for their commercial agreement.
    3. Their CA incorporation + governance bylaws contain a charter provision that limits indemnification ceilings — relevant if any product-liability claim escalates.
    4. The 10-K describes board oversight of regulatory matters as quarterly — post-Pfizer Caremark refresh strongly suggests monthly is the new floor.
    5. No CFO change in 2 years; CFO is the GC\'s primary internal counterweight on outside-counsel relationships.

    Among 14 mid-cap biotech GCs in CB\'s life-sciences cohort, FDA AI/ML guidance is the #1 most-engaged issue this week, with cohort engagement 7 weeks ahead of press coverage. The 340B fallout is the second issue and engagement is concentrated among GCs with single-source commercial agreements (Halcyon fits). Caremark refresh is rising; CA-incorporated biotechs are under-engaging relative to DE-incorporated peers — a soft spot Halcyon shares with two unrepresented peers in your geo.

    Halcyon\'s GC engagement on FDA AI/ML guidance is below the cohort 25th percentile. This is the named blind spot that opens the meeting.

    FDA AI/ML readiness memo 340B contract revisit Board oversight cadence — Caremark refresh CA bylaw refresh on indemnification Diagnostic-AI product-liability framework

    "How is your board planning to handle the FDA AI/ML pre-market clearance pathway for your pipeline — particularly for the four submissions in flight that pre-date the September draft?"

    M&A
    Anatomy of a Public-Company Merger

    Definitive agreement → proxy → close. Every gate, every covenant, every fiduciary moment.

    Open →
    M&A
    Fiduciary Duty Doctrine: Revlon · Unocal · Corwin · MFW

    When each standard applies, how cleansing works, and the post-Pfizer recalibration.

    Open →
    M&A
    Deal Protection: matching rights, no-shops, force-the-vote

    Modern deal protection package and the points that still get litigated.

    Open →
    Capital Markets
    IPO Mechanics: S-1 → Pricing → Lock-up

    Every milestone in a standard public offering, from organizational meeting through the 25th day.

    Open →
    Capital Markets
    Reg FD & MNPI in the AI era

    When a model output becomes material; selective-disclosure traps in algorithmic IR.

    Open →
    PE / Finance
    NVCA Term-Sheet Anatomy

    Liquidation preferences, board composition, anti-dilution — what's market and what's outlier in 2026.

    Open →
    PE / Finance
    Continuation Funds & GP-Led Secondaries

    ILPA template walkthrough; conflict waivers; LP advisory committee process.

    Open →
    PE / Finance
    Private Credit: Unitranche, NAV loans, Sub Lines

    Structures, covenant packages, and the SEC's tightening posture on disclosure.

    Open →